<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384107</url>
  </required_header>
  <id_info>
    <org_study_id>V114-033</org_study_id>
    <secondary_id>V114-033</secondary_id>
    <secondary_id>2019-003644-68</secondary_id>
    <secondary_id>205287</secondary_id>
    <nct_id>NCT04384107</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and immunogenicity of a 4-dose&#xD;
      schedule (3-dose primary series followed by a toddler dose) of V114 compared with&#xD;
      Pneumococcal 13-valent Conjugate Vaccine (PCV13). The hypotheses are that: 1) V114 is&#xD;
      non-inferior to PCV13 for the 13 shared serotypes between V114 and PCV13 based on the&#xD;
      response rates at 30 days following dose 3; 2) V114 is non-inferior to PCV13 for the 2 unique&#xD;
      V114 serotypes based on the response rate of the 2 unique V114 serotypes at 30 days following&#xD;
      dose 3; 3) V114 is non-inferior to PCV13 for the 13 shared serotypes between V114 and PCV13&#xD;
      based on anti-pneumococcal polysaccharide (PnPs) serotype-specific Immunoglobulin G (IgG)&#xD;
      geometric mean concentrations (GMCs) at 30 days following dose 3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">November 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Solicited Injection-Site Adverse Events</measure>
    <time_frame>Day 1 to Day 14 post any vaccination</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs could be swelling, redness, pain or tenderness, and hard lump.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Solicited Systemic AEs</measure>
    <time_frame>Day 1 to Day 14 post any vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs could be irritability, drowsiness, appetite loss, and hives or welts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Vaccine-Related Serious Adverse Events</measure>
    <time_frame>~1 month after Dose 4 (Up to 23 months)</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Meeting the Serotype Specific Immunoglobulin G Threshold Value of ≥0.35 μg/mL for Each Serotype in V114 After Dose 3</measure>
    <time_frame>30 Days after Dose 3</time_frame>
    <description>Assess the anti-pneumococcal polysaccharide (PnPs) serotype-specific immunoglobulin G (IgG) response rates (percentage of participants meeting serotype-specific IgG threshold value of ≥0.35 μg/mL of participants administered V114 versus participants administered PCV13) for the 15 serotypes contained in V114.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Serotype-Specific IgG for the 13 Shared Serotypes in V114 and PCV13 After Dose 3</measure>
    <time_frame>30 Days after Dose 3</time_frame>
    <description>Assess the anti-PnPs serotype-specific IgG geometric mean concentrations (GMCs) of participants administered V114 versus participants administered PCV13 for the 13 shared serotypes in V114 and PCV13.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMC of Serotype-Specific IgG for the 2 Unique V114 Serotypes After Dose 3</measure>
    <time_frame>30 days after Dose 3</time_frame>
    <description>Assess the anti-PnPs serotype-specific IgG GMCs of participants administered V114 versus participants administered PCV13 for the 2 unique V114 serotypes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Serotype Specific IgG Threshold Value of ≥0.35 μg/mL for Each Serotype in V114 After Dose 4</measure>
    <time_frame>30 Days after Dose 4</time_frame>
    <description>Assess the anti-PnPs serotype-specific IgG response rates (percentage of participants meeting serotype-specific IgG threshold value of ≥0.35 μg/mL of participants administered V114 versus participants administered PCV13) for the 15 serotypes contained in V114.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMC of Serotype-Specific IgG for Each Serotype in V114 After Dose 4</measure>
    <time_frame>30 Days after Dose 4</time_frame>
    <description>Assess the anti-PnPs serotype-specific IgG GMCs of participants administered V114 versus participants administered PCV13 for the 15 serotypes contained in V114.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serotype-Specific Opsonophagocytic Activity for Each Serotype in V114 After Dose 3</measure>
    <time_frame>30 Days after Dose 3</time_frame>
    <description>Assess the anti-PnPs serotype-specific opsonophagocytic activity (OPA) and geometric mean titers (GMTs) of participants administered V114 versus participants administered PCV13 for the 15 serotypes contained in V114.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Serotype-Specific OPA for Each Serotype in V114 After Dose 4</measure>
    <time_frame>30 Days after Dose 4</time_frame>
    <description>Assess the anti-PnPs serotype-specific OPA and GMTs of participants administered V114 versus participants administered PCV13 for the 15 serotypes contained in V114.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL subcutaneous injection of V114 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pneumococcal 13-valent Conjugate Vaccine (PCV13)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL subcutaneous injection of PCV13 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>Subcutaneous 0.5 mL single dose</description>
    <arm_group_label>V114</arm_group_label>
    <other_name>VAXNEUVANCE™</other_name>
    <other_name>Pneumococcal 15-Valent Conjugate Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13</intervention_name>
    <description>Subcutaneous 0.5 mL single dose</description>
    <arm_group_label>Pneumococcal 13-valent Conjugate Vaccine (PCV13)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Japanese male or female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of invasive pneumococcal disease (IPD)&#xD;
&#xD;
          -  Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine&#xD;
             (PCV), or any diphtheria toxoid containing vaccine.&#xD;
&#xD;
          -  Has a known or suspected impairment of immunological function.&#xD;
&#xD;
          -  Has a history of congenital or acquired immunodeficiency.&#xD;
&#xD;
          -  Has or his/her mother has a documented human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Has or his/her mother has a documented hepatitis B surface antigen-positive test.&#xD;
&#xD;
          -  Has known or history of functional or anatomic asplenia.&#xD;
&#xD;
          -  Has a history of autoimmune disease .&#xD;
&#xD;
          -  Has a known neurologic or cognitive behavioral disorder&#xD;
&#xD;
          -  Has received a dose of any pneumococcal vaccine prior to study entry.&#xD;
&#xD;
          -  Has received a blood transfusion or blood products, including immunoglobulins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Morinaga Maternity Clinic ( Site 3345)</name>
      <address>
        <city>Kasugai</city>
        <state>Aichi</state>
        <zip>486-0836</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Medical Corporation Koujunkai Daido Clinic ( Site 3326)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoritsu Narashinodai Hospital ( Site 3332)</name>
      <address>
        <city>Funabashi</city>
        <state>Chiba</state>
        <zip>274-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotobo Children's Clinic ( Site 3323)</name>
      <address>
        <city>Isumi</city>
        <state>Chiba</state>
        <zip>299-4503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokoyama Children's Clinic ( Site 3309)</name>
      <address>
        <city>Kasuga</city>
        <state>Fukuoka</state>
        <zip>816-0801</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chugoku Rosai Hospital ( Site 3340)</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuchiura Kyodo General Hospital ( Site 3327)</name>
      <address>
        <city>Tsuchiura</city>
        <state>Ibaraki</state>
        <zip>300-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima Children's Hospital ( Site 3342)</name>
      <address>
        <city>Hioki</city>
        <state>Kagoshima</state>
        <zip>899-2503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawasaki Municipal Hospital ( Site 3302)</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>210-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sagamihara National Hospital ( Site 3303)</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JOHAS Yokohama Rosai Hospital ( Site 3343)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>222-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Mie Chuo Medical Center ( Site 3308)</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sendai Medical Center ( Site 3311)</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ina Central Hospital ( Site 3346)</name>
      <address>
        <city>Ina</city>
        <state>Nagano</state>
        <zip>396-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aizawa Hospital ( Site 3313)</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taniguchi Hospital ( Site 3310)</name>
      <address>
        <city>Izumisano</city>
        <state>Osaka</state>
        <zip>598-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical corporation Waffle GunGunkids Clinic ( Site 3329)</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>591-8023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suita Municipal Hospital ( Site 3338)</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>564-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takatsuki General Hospital ( Site 3318)</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aiwa Hospital ( Site 3336)</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kawaguchi General Hospital ( Site 3304)</name>
      <address>
        <city>Kawaguchi</city>
        <state>Saitama</state>
        <zip>332-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hara Children's Clinic ( Site 3339)</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-1141</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Saitama Hospital ( Site 3312)</name>
      <address>
        <city>Wako</city>
        <state>Saitama</state>
        <zip>351-0102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Shiga Hospital ( Site 3349)</name>
      <address>
        <city>Ritto</city>
        <state>Shiga</state>
        <zip>520-3046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobayashi Pediatric Clinic ( Site 3301)</name>
      <address>
        <city>Fujieda</city>
        <state>Shizuoka</state>
        <zip>426-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiwai Kodomo Clinic ( Site 3331)</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>190-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishida Kodomo Clinic ( Site 3306)</name>
      <address>
        <city>Tama</city>
        <state>Tokyo</state>
        <zip>206-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukui Aiiku Hospital ( Site 3315)</name>
      <address>
        <city>Fukui</city>
        <zip>910-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukui-ken Saiseikai Hospital ( Site 3314)</name>
      <address>
        <city>Fukui</city>
        <zip>918-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shindo Children's Clinic ( Site 3325)</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0121</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurokawa Michiko Pediatric Clinic ( Site 3319)</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimomura Pediatrics Clinic ( Site 3320)</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INAMITSU Children's Clinic ( Site 3321)</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagamine Soyokaze Clinic ( Site 3348)</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-0920</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minaminagano Medical Center Shinonoi General Hospital ( Site 3344)</name>
      <address>
        <city>Nagano</city>
        <zip>388-8004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Noe Hospital ( Site 3330)</name>
      <address>
        <city>Osaka</city>
        <zip>536-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kubota Children's Clinic ( Site 3334)</name>
      <address>
        <city>Osaka</city>
        <zip>544-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sano Kids Clinic ( Site 3341)</name>
      <address>
        <city>Osaka</city>
        <zip>553-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aizenbashi Hospital ( Site 3317)</name>
      <address>
        <city>Osaka</city>
        <zip>556-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Shizuoka Hospital ( Site 3322)</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka City Shimizu Hospital ( Site 3347)</name>
      <address>
        <city>Shizuoka</city>
        <zip>424-8636</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosaka Children's Clinic ( Site 3307)</name>
      <address>
        <city>Tokyo</city>
        <zip>112-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fraternity Memorial Hospital ( Site 3333)</name>
      <address>
        <city>Tokyo</city>
        <zip>130-8587</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okawa Children &amp; Family Clinic ( Site 3305)</name>
      <address>
        <city>Tokyo</city>
        <zip>146-0095</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyama City Hospital ( Site 3328)</name>
      <address>
        <city>Toyama</city>
        <zip>939-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

